$CLDX, ProShare Advisors LLC Has $1,469,000 Stake
Post# of 22755
Posted On: 04/01/2016 3:49:50 PM
$CLDX, ProShare Advisors LLC Has $1,469,000 Stake in Celldex Therapeutics, Inc. (CLDX)
Posted by Reagan on Apr 1st, 2016 // No Comments
Celldex Therapeutics logoProShare Advisors LLC boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 10.7% during the fourth quarter, Holdings Channel reports. The fund owned 93,666 shares of the biopharmaceutical company’s stock after buying an additional 9,072 shares during the period. ProShare Advisors LLC owned about 0.09% of Celldex Therapeutics worth $1,469,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale increased its position in shares of Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock worth $808,000 after buying an additional 500 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock worth $2,862,000 after buying an additional 2,946 shares during the last quarter. Rhumbline Advisers increased its position in shares of Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Celldex Therapeutics by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 257,436 shares of the biopharmaceutical company’s stock worth $4,037,000 after buying an additional 13,652 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Celldex Therapeutics by 22.3% in the fourth quarter. Nationwide Fund Advisors now owns 115,044 shares of the biopharmaceutical company’s stock worth $1,804,000 after buying an additional 20,996 shares during the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 3.44% during midday trading on Friday, hitting $3.91. 1,699,531 shares of the company traded hands. The company’s market cap is $385.93 million. Celldex Therapeutics, Inc. has a 12-month low of $2.96 and a 12-month high of $30.28. The stock has a 50 day moving average price of $5.32 and a 200-day moving average price of $11.34.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.02. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.80 million. Celldex Therapeutics’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.36) EPS. Analysts expect that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current year.
A number of brokerages have commented on CLDX. Wedbush downgraded shares of Celldex Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research report on Monday, March 7th. Leerink Swann downgraded shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $30.00 to $4.00 in a research report on Monday, March 7th. Oppenheimer downgraded shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 7th. Jefferies Group downgraded shares of Celldex Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $31.00 to $4.00 in a report on Monday, March 7th. Finally, Roth Capital reiterated a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Seven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Celldex Therapeutics has a consensus rating of “Hold” and a consensus target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Posted by Reagan on Apr 1st, 2016 // No Comments
Celldex Therapeutics logoProShare Advisors LLC boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 10.7% during the fourth quarter, Holdings Channel reports. The fund owned 93,666 shares of the biopharmaceutical company’s stock after buying an additional 9,072 shares during the period. ProShare Advisors LLC owned about 0.09% of Celldex Therapeutics worth $1,469,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale increased its position in shares of Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock worth $808,000 after buying an additional 500 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock worth $2,862,000 after buying an additional 2,946 shares during the last quarter. Rhumbline Advisers increased its position in shares of Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Celldex Therapeutics by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 257,436 shares of the biopharmaceutical company’s stock worth $4,037,000 after buying an additional 13,652 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Celldex Therapeutics by 22.3% in the fourth quarter. Nationwide Fund Advisors now owns 115,044 shares of the biopharmaceutical company’s stock worth $1,804,000 after buying an additional 20,996 shares during the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 3.44% during midday trading on Friday, hitting $3.91. 1,699,531 shares of the company traded hands. The company’s market cap is $385.93 million. Celldex Therapeutics, Inc. has a 12-month low of $2.96 and a 12-month high of $30.28. The stock has a 50 day moving average price of $5.32 and a 200-day moving average price of $11.34.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.02. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.80 million. Celldex Therapeutics’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.36) EPS. Analysts expect that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current year.
A number of brokerages have commented on CLDX. Wedbush downgraded shares of Celldex Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research report on Monday, March 7th. Leerink Swann downgraded shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $30.00 to $4.00 in a research report on Monday, March 7th. Oppenheimer downgraded shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 7th. Jefferies Group downgraded shares of Celldex Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $31.00 to $4.00 in a report on Monday, March 7th. Finally, Roth Capital reiterated a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Seven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Celldex Therapeutics has a consensus rating of “Hold” and a consensus target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼